+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Adrenocortical Carcinoma Drugs Market 2019-2023 - Product Image

Global Adrenocortical Carcinoma Drugs Market 2019-2023

  • ID: 4807739
  • Report
  • Region: Global
  • 114 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • MORE
Global Adrenocortical Carcinoma Drugs Market: About this market

Adrenocortical carcinoma drugs significantly include chemotherapeutics. The adrenocortical carcinoma drugs market analysis considers sales from chemotherapy and targeted therapy segments. Our analysis also considers the sales of adrenocortical carcinoma drugs Asia, Europe, North America, and ROW. In 2018, the chemotherapy segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as increased survival rate and effectivity will significantly help the chemotherapy segment in maintaining its leading market position. Also, our global adrenocortical carcinoma drugs report has observed market growth factors such as increasing prevalence of genetic disorders leading to adrenocortical carcinoma, regulatory incentives, and advantages of novel drugs over chemotherapeutics. However, lack of effective therapies, lack of preclinical models for testing novel therapeutics, and side-effects of drugs may hamper the growth of the adrenocortical carcinoma drugs industry over the forecast period.

Global Adrenocortical Carcinoma Drugs Market: Overview

Advantages of novel drugs over chemotherapeutics

Novel therapies have minimal side effects and longer survival rate compared with chemotherapeutics. As a result, the development and approval of novel therapies are increasing, augmenting the sales of vendors. These factors will lead to the expansion of the global adrenocortical carcinoma drugs market at a CAGR of over 6% during the forecast period.

Advances in imaging techniques for adrenal tumors

Advances in imaging techniques are facilitating enhanced diagnostic accuracy for adrenocortical carcinoma in a non-invasive manner. This is assisting healthcare professionals in treating patients effectively by administering appropriate therapeutics and drugs. As a result, the sales of adrenocortical carcinoma drugs will increase. Therefore, this trend will have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global adrenocortical carcinoma drugs market during the forecast period 2019-2023, contact us.

Competitive Landscape

With the presence of a few major players, the global adrenocortical carcinoma drugs market is concentrated. The robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading Adrenocortical carcinoma drugs manufacturers, which include Bristol-Myers Squibb Co., Eli Lilly and Co., Laboratoire HRA Pharma SAS, Progenics Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd.

Also, the adrenocortical carcinoma drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Chemotherapy - Market size and forecast 2018-2023
  • Targeted therapy - Market size and forecast 2018-2023
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Increasing R&D for adrenocortical carcinoma
  • Advances in imaging techniques for adrenal tumors
  • Emergence of new diagnostic methods
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Laboratoire HRA Pharma SAS
  • Progenics Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
PART 15: EXPLORE AUTHOR

List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 22: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Targeted therapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Drugs under development
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 46: Bristol-Myers Squibb Co. - Business segments
Exhibit 47: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 48: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 49: Bristol-Myers Squibb Co. - Key offerings
Exhibit 50: Eli Lilly and Co. - Vendor overview
Exhibit 51: Eli Lilly and Co. - Business segments
Exhibit 52: Eli Lilly and Co. - Organizational developments
Exhibit 53: Eli Lilly and Co. - Geographic focus
Exhibit 54: Eli Lilly and Co. - Segment focus
Exhibit 55: Eli Lilly and Co. - Key offerings
Exhibit 56: Laboratoire HRA Pharma SAS - Vendor overview
Exhibit 57: Laboratoire HRA Pharma SAS - Key offerings
Exhibit 58: Progenics Pharmaceuticals Inc. - Vendor overview
Exhibit 59: Progenics Pharmaceuticals Inc. - Business segments
Exhibit 60: Progenics Pharmaceuticals Inc. - Organizational developments
Exhibit 61: Progenics Pharmaceuticals Inc. - Key offerings
Exhibit 62: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 63: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 64: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 65: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 66: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 67: Validation techniques employed for market sizing
Exhibit 68: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Laboratoire HRA Pharma SAS
  • Progenics Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll